June 17, 2011

Punitive Damages awarded by Indian Court for infringement of trademark

Introduction

The Delhi High Court (“Delhi HC”) in the case of Pfizer Products Inc. & Anr. (“Plaintiffs”) vs. B.P. Singh Tyagi & Anr.(“Defendants”)1 granted injunction against Omax Healthcare Pvt. Ltd. (“Defendant No.2”) from manufacture and sale of its product being phonetically and deceptively similar to the registered trademark of the Plaintiffs and punitive damages of INR 1 lakh for act of infringement.

Facts of the Case

The Plaintiffs are subsidiaries of Pfizer, a large multinational pharmaceutical company with global reputation for high quality products. COREX, a cough syrup is one of the top selling products of the company and is sold in India from 1964. The mark COREX was registered in India under Class 5 vide Trademark No. 213825 since 1963.

The Plaintiffs have filed a suit for injunction, rendition of accounts and damages against the Defendants for marketing their cough syrup under the mark “OREX” being phonetically and deceptively similar to their registered mark being “COREX”.

Plaintiff’s Submissions

It was the submission of the Plaintiffs that usage of the mark “OREX” by the Defendants being deceptively and phonetically similar to the Plaintiff’s mark leads to confusion in the minds of the customers. The Plaintiffs also contended that usage of such mark by the Defendants could lead to harming their goodwill and reputation in the market along with creating an impression that the mark was associated with the Plaintiffs. The matter has been proceeded ex-parte as the Defendants did not appear in the matter.

Decision and Rationale

The Delhi HC granted injunction restraining the Defendant No. 2 from manufacturing, marketing and distributing cough syrup under the mark “OREX” or any mark deceptively similar to that of the Plaintiffs and awarded payment of INR 1 lakh as punitive damages.

The Delhi HC placed reliance on its earlier decision Pfizer Products, Inc and Anr. vs. Vijay Shah and Ors.2 wherein it had examined the infringement of Plaintiff’s mark in respect of defendant’s cough syrup “SOREX”. The Delhi HC had discussed the entire jurisprudence on trademark infringement with respect to statutory rights provided under the Trademarks Act, 1999 and claims of passing off under common law.

The question that arises for consideration is whether two competing marks are so similar to create confusion in the minds of people having average intelligence and imperfect recollection. The mark should not create any confusion with regard to the source of the product and business interests of honest manufacturers need to be protected.

It is a settled law that any party using a mark, visually, phonetically and deceptively similar to that of a registered trademark creating confusion in the minds of the customers, would lead to claims of infringement and passing off. Fraudulent usage of deceptive mark amounts to false misrepresentation to the public. No party is allowed to use marks of competitors with the intention of usurping their goodwill and reputation in the market. Colourable usage of marks is not permissible or enrichment upon the brand value created by others.

Despite statutory requirements, cough syrup being one of the most commonly sold drugs is readily available without prescription. People possessing average intelligence and staying in villages might not be vigilant enough to check minute details and products sold with visual and phonetic similarity may cause confusion among customers. Quality of all goods is not similar and could adversely affect the reputation of the registered trademark owner.

On the basis of the above reasoning and trademark jurisprudence in India, the Delhi HC granted injunction against the manufacture, sale and distribution of cough syrup of the defendants under the name of “OREX” or any other name/mark which is phonetically and deceptively similar to the registered mark “COREX”. No actual damages or profits earned by the Defendants on account of deceptive and phonetic similarity of the mark were proved.  Thus, no actual damages have been awarded but to deter the Defendants from usage of such deceptively similar trademarks, punitive damages have been awarded.

Conclusion

The law for infringement of trademarks and passing off has being established through a series of judgments. However, in the present case to deter the Defendants from using phonetically and deceptively similar trademarks punitive damages have been awarded though no actual damages have been established. This move would create deterrence in the minds of users resorting to fraudulent usage/infringing registered marks of established manufacturers and preventing confusion in the minds of customers.

 

 

­­­__________________

1 MANU/DE/2146/2011

2 2011 (45) PTC 176 (Del)

 

 

- Payel Chatterjee, Vyapak Desai & Vivek Kathpalia

You can direct your queries or comments to the authors

 

 

Management by Trust in a Democratic Enterprise: A Law Firm Shapes Organizational Behavior to Create Competitive Advantage, Global Business and Organizational Excellence,

Sep 2009

NDA: A different approach by Shyamal Majumdar, Business Standard, July 23, 2009.

A law firm head spends his time studying organisa

ional behavior.

Nishith Desai: Honoured with the title of "Prof. Yunus Social Business Pioneer of India" - 2010 by The Grameen Lab and the Wockhardt Foundation

Legal 500: Ranked in Tier 1 for Tax, TMT and Investment Funds

Nishith Desai: Featured in the Lex Witness publication ‘Witness Hall of Fame: Top 50’ - August 2010

 

>>>

Acquiring India - now a competitive task!, Legal Era

 Akshay Bhargav & Simone Reis, June 06, 2011

Dealing with the new competition laws, The Hindu, Business Line, Ruchi Biyani & Simone R

is, May 30, 2011

Cairn-Vedanta Deal: Legal Issues May Land Govt. In Trouble, VCCircle, Prateek Bagaria & Vyapak Desai, May 27, 2011

Cairn-Vedanta deal: Govt must be conscious of legal hiccups, The Economic Times, Prateek Bagaria & Vyapak Desai, May 27, 2011

Doing Business in India

Joint Ventures in India

Mergers & Acquisitions in India

Dispute Resolution in India

Real Estate Investment

>>>

Indian Merger Control Regulations Finally Notified, May 19, 2011

Overview of the UCITS regime: The Luxembourg and Dublin experiences; tax efficiencies, April 29, 2011

New Consolidated Foreign Direct Investment Policy, April 7, 2011

FCPA issues with a special focus on India, March 14, 2011

>>>

 

Welcome to connect with us at interesting conferences, seminars and events.

>>>

 

Introducing NDA Dialawgue and Deal Destination.

Siddharth Shah on CNBC TV - 18: Cairn – Vedanta deadlock: Should a third party step in ?, April 08, 2011

Nishchal Joshipura on CNBC TV - 18: To exempt or not to exempt?, April 8, 2011

Siddharth Shah on CNBC TV - 18: SmartLink move not smart enough for shareholders, April 01, 2011

Nishith Desai on CNBC TV 18: Chasing black money!, Feb 12, 2011

>>>

 

Click here to view Hotline archives.

Funding Real Estate Projects - Exit Challenges, April 28, 2011

Real Estate in India - A Practical Insight, March 22, 2011

>>>

Hero to ride without its 'Pillion Rider', March 15, 2011

Piramal - Abbott Deal: The Great Indian Pharma Story, Aug 05, 2010

>>>

 

Our email newsletters – Hotlines are very popular for their insights and analysis. Sign-up to receive Hotlines on the following – Tax, CorpSec, HR, Dispute Resolution and our regular updates such as M&A Labs, IP, Pharma, Media, Telecom Updates and Budget and Policy Analyses.

 

Please visit www.nishithdesai.com to access our Research online.

 

Unsubscribe

 

Feedback

Disclaimer: The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

This Hotline provides general information existing at the time of preparation. The Hotline is intended as a news update and Nishith Desai Associates neither assumes nor accepts any responsibility for any loss arising to any person acting or refraining from acting as a result of any material contained in this Hotline. It is recommended that professional advice be taken based on the specific facts and circumstances. This Hotline does not substitute the need to refer to the original pronouncements. 

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.